BioSpace News Archive

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) announces that the Company’s condensed consolidated interim financial statements for the six months ended June 30, 2023 and corresponding management discussion and analysis have been amended

Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key milestones achieved during H1 2023 as well as the Company’s outlook for its immunotherapies in immuno-oncology and immuno-inflammation.

A historic transplant of a genetically modified pig heart has been successfully performed on a 20-year Navy veteran and married father of two suffering from end-stage cardiovascular disease.

The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠ datasets

4WEB Medical announced that it has received 510K clearance to market the newest additions to the company’s implant portfolio, the Cervical Spine Truss System (CSTS) Integrated Plating Solution and two cervical interbody line extensions which include implants with 12 degrees of lordosis and an option for a large footprint (16mm x19mm).

Acuitive Technologies, Inc. announced the FDA 510 Clearance of CITRELOCK DUO Fixation Device for biceps tenodesis.

QIAGEN announced the release of its Sustainability Report 2022, emphasizing its unwavering focus on driving positive change for society through its goals for Environment, Social and Governance metrics.

Delcath Systems, Inc. announces that the Company granted equity awards, in the form of a total of 86,000 shares of the Company’s common stock, outside of the Company’s Omnibus 2020 Equity Incentive Plan as amended, previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires.

Cellectis announced that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting, that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego.